|Videos|May 19, 2020

Are There Several Strains of SARS-CoV-2?

Adam Brufsky, MD, discusses the potential of multiple SARS-CoV-2 viral strains.

Part 1: Adam Brufsky, MD, medical oncologist, UPMC Hillman Cancer Center, discusses the potential for several SARS-CoV-2 viral strains in the COVID-19 outbreak.

Segment Description:

Adam M. Brufsky, Professor of Medicine at the University of Pittsburgh, explains emerging theories which could change our understanding of SARS-CoV-2. Dr. Brufsky is a medical oncologist, and in the first part of the interview brings his outside expertise to discuss the potential role of hyperglycemia in severity of COVID-19. Dr. Brufsky has contributed articles to several journals, working with experts native to the infectious disease field.

In part 1, Dr. Brufsky explains how hyperglycemia, and not simply diabetes, may lead to more severe COVID‐19 disease. This would be because both the virus and the ACE2 receptor it attaches to require sugar molecules bound to their protein for the binding to take place. So severity of coronavirus, this would mean, is mediated by the concentration of sugar-coated virus and sugar-coated ACE2 receptors in a patient's lung tissues.

In part 2, Dr. Brufsky explains a second interesting conclusion: that there are 2 strains of the virus, with different virulence. On the US west coast, for example, there may be a less lethal strain in circulation than the east coast and some of the European countries that have been hardest hit.

And part 3 is where it gets both optimistic and controversial: Dr. Brufsky speculates that the virus may be attenuating over time. While many look back at the original SARS' decline as solely the result of public health measures, there's a school of thought that points to the possibility changes in the virus had a role.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.